|
Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Incyte (Inst) |
|
|
No Relationships to Disclose |
|
Catherine S. Magid Diefenbach |
Stock and Other Ownership Interests - Gilead Sciences |
Consulting or Advisory Role - Celgene; Idera; Immunogen; Immunogen; Janssen Oncology; Seagen |
Speakers' Bureau - Gilead Sciences; Seagen |
Research Funding - Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Molecular Templates (Inst); Seagen (Inst) |
|
|
Consulting or Advisory Role - ARIAD; Novartis; Pfizer |
Research Funding - ARIAD; Incyte; Novartis; Pfizer; Sanofi |
Travel, Accommodations, Expenses - ARIAD; Incyte; Novartis; Pfizer |
|
|
|
Stock and Other Ownership Interests - Incyte |
|
|
|
Stock and Other Ownership Interests - Incyte |
|
|
|
Stock and Other Ownership Interests - Incyte |
|
|
|
Stock and Other Ownership Interests - Incyte |
|
|
|
Stock and Other Ownership Interests - Incyte |
|
|
|
Stock and Other Ownership Interests - Incyte |
|
|
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics; TG Therapeutics |
Research Funding - Pharmacyclics |